News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
653,307 Results
Type
Article (49921)
Company Profile (223)
Press Release (603138)
Multimedia
Podcasts (184)
Webinars (29)
Section
Business (178076)
Career Advice (2612)
Deals (32834)
Drug Delivery (155)
Drug Development (79635)
Employer Resources (172)
FDA (16708)
Job Trends (13778)
News (315930)
Policy (32809)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2457)
Academic (1)
Accelerated approval (45)
Adcomms (37)
Allergies (157)
Alliances (45038)
ALS (194)
Alzheimer's disease (1817)
Antibody-drug conjugate (ADC) (391)
Approvals (16918)
Artificial intelligence (618)
Autoimmune disease (232)
Automation (39)
Bankruptcy (330)
Best Places to Work (10191)
BIOSECURE Act (23)
Biosimilars (215)
Biotechnology (113)
Bladder cancer (177)
Brain cancer (63)
Breast cancer (668)
Cancer (5217)
Cardiovascular disease (455)
Career advice (2206)
Career pathing (44)
CAR-T (285)
CDC (71)
Celiac Disease (1)
Cell therapy (811)
Cervical cancer (39)
Clinical research (68625)
Collaboration (1833)
Company closure (6)
Compensation (1271)
Complete response letters (90)
COVID-19 (2806)
CRISPR (97)
C-suite (953)
Cystic fibrosis (146)
Data (6775)
Decentralized trials (3)
Denatured (51)
Depression (169)
Diabetes (542)
Diagnostics (6056)
Digital health (45)
Diversity (12)
Diversity, equity & inclusion (43)
Drug discovery (294)
Drug pricing (231)
Drug shortages (36)
Duchenne muscular dystrophy (280)
Earnings (74863)
Editorial (70)
Employer branding (20)
Employer resources (152)
Events (101073)
Executive appointments (1010)
FDA (20101)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (25)
Funding (1490)
Gene editing (213)
Generative AI (55)
Gene therapy (686)
GLP-1 (1160)
Government (4403)
Grass and pollen (8)
Guidances (390)
Healthcare (16131)
HIV (76)
Huntington's disease (57)
IgA nephropathy (93)
Immunology and inflammation (309)
Immuno-oncology (84)
Indications (152)
Infectious disease (3120)
Inflammatory bowel disease (210)
Inflation Reduction Act (15)
Influenza (124)
Intellectual property (263)
Interviews (480)
IPO (15518)
IRA (59)
Job creations (3881)
Job search strategy (1816)
JPM (73)
Kidney cancer (19)
Labor market (94)
Layoffs (635)
Leadership (45)
Legal (7941)
Liver cancer (99)
Longevity (26)
Lung cancer (697)
Lymphoma (396)
Machine learning (48)
Management (59)
Manufacturing (912)
MASH (187)
Medical device (12014)
Medtech (12080)
Mergers & acquisitions (18429)
Metabolic disorders (1508)
mRNA (203)
Multiple sclerosis (178)
NASH (24)
Neurodegenerative disease (396)
Neuropsychiatric disorders (111)
Neuroscience (3253)
Neurotech (2)
NextGen: Class of 2026 (5543)
Non-profit (3471)
Now hiring (63)
Obesity (753)
Opinion (337)
Ovarian cancer (168)
Pain (226)
Pancreatic cancer (249)
Parkinson's disease (352)
Partnered (29)
Patents (545)
Patient recruitment (573)
Peanut (60)
People (54384)
Pharmaceutical (86)
Pharmacy benefit managers (35)
Phase 1 (21183)
Phase 2 (29806)
Phase 3 (23189)
Pipeline (6723)
Policy (364)
Postmarket research (2611)
Preclinical (8629)
Press Release (50)
Prostate cancer (279)
Psychedelics (60)
Radiopharmaceuticals (300)
Rare diseases (1054)
Real estate (5456)
Recruiting (70)
Regulatory (25510)
Reports (47)
Research institute (2308)
Resumes & cover letters (430)
Rett syndrome (32)
RNA editing (19)
RSV (86)
Schizophrenia (169)
Series A (259)
Series B (192)
Service/supplier (14)
Sickle cell disease (110)
Special edition (29)
Spinal muscular atrophy (170)
Sponsored (49)
Startups (3390)
State (2)
Stomach cancer (21)
Supply chain (123)
Tariffs (101)
The Weekly (130)
Vaccines (1161)
Venture capital (106)
Weight loss (519)
Women's health (97)
Worklife (23)
Date
Last 7 days (597)
Last 30 days (2486)
Last 365 days (29863)
2026 (7316)
2025 (30192)
2024 (33890)
2023 (37955)
2022 (48576)
2021 (52355)
2020 (49729)
2019 (40556)
2018 (30958)
2017 (31273)
2016 (30064)
2015 (33726)
2014 (27398)
2013 (23039)
2012 (24702)
2011 (25296)
2010 (23250)
Location
Africa (802)
Alabama (76)
Alaska (7)
Arizona (271)
Arkansas (13)
Asia (40590)
Australia (6533)
California (11715)
Canada (3087)
China (1204)
Colorado (491)
Connecticut (526)
Delaware (360)
Europe (92250)
Florida (1780)
Georgia (356)
Hawaii (4)
Idaho (47)
Illinois (886)
India (76)
Indiana (493)
Iowa (22)
Japan (483)
Kansas (116)
Kentucky (43)
Louisiana (31)
Maine (77)
Maryland (1445)
Massachusetts (8548)
Michigan (289)
Minnesota (623)
Mississippi (5)
Missouri (125)
Montana (21)
Nebraska (26)
Nevada (125)
New Hampshire (68)
New Jersey (3190)
New Mexico (27)
New York (3069)
North Carolina (1539)
North Dakota (7)
Northern California (5835)
Ohio (324)
Oklahoma (19)
Oregon (38)
Pennsylvania (2287)
Puerto Rico (23)
Rhode Island (40)
South America (1176)
South Carolina (70)
South Dakota (1)
Southern California (4595)
Tennessee (178)
Texas (1778)
United States (41345)
Utah (296)
Virginia (292)
Washington D.C. (81)
Washington State (929)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
653,307 Results for "ascendis pharma a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One
Prime biotech buyout targets such as Revolution Medicines and Ascendis Pharma have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.
March 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
March 2, 2026
·
4 min read
Press Releases
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
February 12, 2026
·
14 min read
Press Releases
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
February 5, 2026
·
4 min read
FDA
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
December 1, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
3 min read
Press Releases
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
·
10 min read
Press Releases
Ascendis Pharma Reports Third Quarter 2025 Financial Results
November 13, 2025
·
13 min read
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease.
October 13, 2025
·
7 min read
·
Tristan Manalac
Approvals
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug
Yuviwel will compete with BioMarin’s Voxzogo. Meanwhile, BridgeBio is working to bring its own achondroplasia drug, the FGFR3 blocker infigratinib, to the market.
March 2, 2026
·
2 min read
·
Tristan Manalac
1 of 65,331
Next
